Healthcare / BiotechnologyNasdaqGS
$8.23
-0.35 (-4.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-275.7M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$531M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.6%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+55.8%
FCF CAGR
—
FCF margin
-105.0%
FCF / Net income
3.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $262.6M · net income $-80.8M · FCF $-275.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $262.6M | $262.6M | $263.4M | $78.5M | $131.4M | $46.7M | $21.8M | $18.3M | $14.3M | $7.6M |
| Net Income | $-80.8M | $-80.8M | $-198.9M | $-367.3M | $-282.5M | $-191.0M | $-119.3M | $-70.3M | $-41.5M | $-24.0M |
| EBITDA | $-113.3M | $-113.3M | $-243.6M | $-394.8M | $-255.0M | $-183.6M | $-117.6M | $-49.9M | $-43.1M | $-24.4M |
| EPS | — | — | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -2.13 | — | — |
| Operating Margin | -45.1% | -45.1% | -95.0% | -511.5% | -200.3% | -403.4% | -554.1% | -281.4% | -306.3% | -326.7% |
| Net Margin | -30.8% | -30.8% | -75.5% | -467.9% | -215.0% | -409.0% | -547.2% | -384.2% | -290.1% | -317.3% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.00 |
| Current Ratio | 5.44 | 5.44 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-275.7M | $-275.7M | $-261.1M | $-350.7M | $-280.3M | $554.7M | $-96.1M | $-46.9M | $-18.9M | $4.1M |
| Returns | ||||||||||
| ROE | -18.6% | -18.6% | -35.4% | -55.7% | -50.0% | -24.4% | -18.6% | -31.0% | -30.4% | 39.3% |
| Valuation | ||||||||||
| P/B | 1.21 | 1.21 | 2.62 | 3.41 | 3.21 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | -0.3% | -0.3% | 235.5% | -40.3% | — | 114.2% | 19.1% | 28.0% | 88.7% | — |
| EPS Growth | — | — | 58.2% | -24.7% | — | -26.5% | -41.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.77 → n/d
Residual
+12.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.